Rho, a full-service contract research organization (CRO), has acquired Dokumeds, a privately-held European CRO headquartered in Riga, Latvia, Dokumeds, with 10 offices and is active across multiple continents. Financial terms were not disclosed.
 
“Our two companies are a great match, known for long-lasting relationships, scientific excellence and high-quality clinical development services,” said Laura Helms Reece, DrPH, CEO, Rho. “I’m thrilled to expand on our existing partnership and welcome Dokumeds to our company. Our teams are already aligned, ready to drive sponsors’ multinational programs forward to achieve development milestones and bring new and better treatments to patients. With this acquisition, Rho continues to offer focused therapeutic expertise as well as the attentiveness and agility of a medium-sized CRO, now with expanded global reach.”
 
“Dokumeds is delighted to join Rho, a fast-growing company that shares our passion for bringing new and improved therapies to the patients who need them,” said Indra Aboltina, MD, PhD, CEO, Dokumeds. “Our two companies already share a similar business culture and have complementary specialties and geographic footprints. This means that we are well on the way towards swift, smooth integration into a productive new entity that will help sponsors reach milestones more quickly and efficiently – globally.”
 
The combined companies will continue to provide full service clinical development services, from investigational new drug applications to regulatory submissions. Rho and Dokumeds’ organizational fit, operations, and manageable size will enable an accelerated integration process without delays or interruptions to client programs. Clients will benefit from expanded access to patients worldwide, with quality across countries and sites.